Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Year: 2017
Type: conference-abstract
Source: Cancer Research
Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, David Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan Oluwole, Tanya Siddiqi, Yi Lin, John Timmerman, Jonathan W. Friedberg, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
Institutions: Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, University of Miami, Stanford University, Dana-Farber Cancer Institute, Montefiore Medical Center, Vanderbilt University Medical Center, City Of Hope National Medical Center, Mayo Clinic, University of California, Los Angeles, University of Rochester Medicine, University of Rochester
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2741217779